Osaka, Apr 14, 2004 - (JCN Newswire) - Kobayashi Pharmaceutical Co., Ltd. is pleased to announce the launch of a surgical device series for "Portless Endoscopic Surgery : PLES." The new devices are the first product line to have been developed by the Medical Device R&D Center of the Kobayashi Medical Company, a member of the group's Medical Device Operation Division.
"Portless Endoscopic Surgery" (PLES) is primarily characterized by surgical procedures that can be performed through one incision just large enough to access the target. PLES offers the advantages of both conventional abdominal surgery and laparoscopic surgery especially in urology field, enabling the safer procedures.
The concept of "Endoscopic Minilaparotomy" was introduced at a Kobe conference held by the Japanese Urological Association in the Spring of 2001, and was heralded as a breakthrough by urologists, many of whom were in the movement from abdominal surgery towards laparoscopic surgery. Most significantly, PLES contributes to an improved patient QOL (quality of life), since patient stress can be greatly reduced due to the smaller incision, shortened hospital stay, fewer post-operative infections, fewer complications, and better long-term results.
Kobayashi Medical Company is committed to the creation of a healthy and comfortable life with a mission to "contribute to patient's QOL and medical care by delivering state-of-art medical technology and information to the medical marketplace". The launch of this series of PLES surgical devices, the first major new product from the Kobayashi Medical Company, and the many new medical devices the division will introduce in the future follow Kobayashi's dedicated mission.
About Kobayashi's Medical Devices Operation Division
Kobayashi's Medical Devices Operation Division was created in June 1972, when Japan Medico, Inc. (presently Medicon, Inc.) was established. The Medical Device business has grown to become the third pillar of the Kobayashi Pharmaceutical Group along with Consumer Products and Wholesale Operations. The Medical Devices Operation in Japan consists of Medicon, Inc., a joint corporation with C. R. Bard of the US, and Kobayashi Medical Company. Medicon, Inc. is engaged in marketing state-of-the-art C.R.Bard urology and gastrointestinal medical equipment and devices. The Kobayashi Medical Company markets quality medical products related to orthopedics, anesthesiology, neurosurgery, otolaryngology and operating rooms from around the world in Japan. In 2003, its R&D Center was established to develop and refine products that further meet customers' needs.
About Kobayashi Pharmaceutical
Kobayashi Pharmaceutical (TSE: 4967) first opened for business in 1919, and management policy has always been to provide people and society with wonderful comfort through "Creativity and Innovation". Over the years the Company has expanded its scope, developing into a cluster of enterprises with three principal businesses: Consumer Products Operation, Wholesale Operation and Medical Devices Operation. In the fiscal year ended March 31, 2003, Kobayashi achieved increases in sales and profits for the fifth consecutive year since the introduction of consolidated accounting.
https://hint.kobayashi.co.jp/inq/inq0109.html" target="_blank" >Contact Public and Investor Relations
About Kobayashi Pharmaceutical
Kobayashi Pharmaceutical (TSE: 4967; OTC: KBYPF) first opened for business in 1919, and its management policy has always been to provide people and society with wonderful comfort through "Creativity and Innovation". Over the years the Company has expanded its scope, developing into a cluster of enterprises with two principal businesses: Consumer Products Operation and Medical Devices Operation. In the fiscal year ended March 31, 2008, Kobayashi achieved increases in profits for the eleventh consecutive year since the introduction of consolidated accounting. For more information, please visit www.kobayashi.co.jp .
Contact:
Kobayashi Pharmaceutical
Shinichi Katagiri,
Corporate Communications Group
shin.katagiri@kobayashi.co.jp
+81-3-6222-0210
Apr 14, 2004
Source: Kobayashi Pharmaceutical
Kobayashi Pharmaceutical (TSE: 4967) (U.S: KBYPF)
From the Japan Corporate News Network
http://www.japancorp.net
Topic: New Product
View more news from these Sectors: Medical, Medical, Medical, Medical
|
)
